Cours en clôture
Autres places de cotation
|
Varia. 5j. | Varia. 1 janv. | ||
- USD | -.--% |
|
-.--% | -.--% |
CA 2024 * | 145 M 131 M | CA 2025 * | 270 M 242 M | Capitalisation | 1,03 Md 923 M |
---|---|---|---|---|---|
Résultat net 2024 * | -140 M -126 M | Résultat net 2025 * | -51 M -45,86 M | VE / CA 2024 * | 6,09 x |
Trésorerie nette 2024 * | 142 M 128 M | Trésorerie nette 2025 * | 115 M 103 M | VE / CA 2025 * | 3,38 x |
PER 2024 * |
-7,18
x | PER 2025 * |
-20
x | Employés | 244 |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 87,91% |
Dernier transcript sur Tarsus Pharmaceuticals, Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 46 | 01/01/17 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 62 | 24/04/23 |
Sesha Neervannan
COO | Chief Operating Officer | 56 | 16/07/20 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Bill Link
BRD | Director/Board Member | 78 | 01/01/17 |
Wendy Yarno
BRD | Director/Board Member | 68 | 19/11/20 |
Director/Board Member | 69 | 01/12/19 |
![Consensus](/images/consensus_flch.gif)
Révisions de BNA
Varia. 1 janv. | Capi. | |
---|---|---|
+55,32% | 815 Md | |
+44,05% | 641 Md | |
-6,75% | 352 Md | |
+13,56% | 314 Md | |
+10,68% | 303 Md | |
+16,57% | 242 Md | |
+2,04% | 224 Md | |
+13,31% | 218 Md | |
+8,48% | 168 Md |
- Bourse
- Actions
- Action TARS
- Action